cover image: Political Declaration of the High-level Meeting on Antimicrobial Resistance sustainable – EU ADD] leaving no one behind – G77 ADD]

20.500.12592/q7hbkkn

Political Declaration of the High-level Meeting on Antimicrobial Resistance sustainable – EU ADD] leaving no one behind – G77 ADD]

11 Sep 2024

[Enhance – CANZ DEL] [Improve access to and – CANZ ADD] the appropriate use of antimicrobials [for humans and animals – UK ADD] through [the implementation of antimicrobial stewardship programmes and – EU ADD] [better valuation of and – US DEL] investment in [the development of new and improvement of existing – HOLY SEE ADD] innovative, rapid, [effective, validated – CANZ ADD] and affordable [esse. [...] [Underscore the environmental dimensions – EU DEL] [Acknowledge the role of the environment as source of and in the spread of – EU ADD] [and public health threat posed by discharge of antimicrobials and their metabolites into the environment and the need for a range of – CHE ADD] [antimicrobial resistance and the need for – CHE DEL] [multisectoral – EU ADD] priority actions to prevent and address. [...] Note with concern the inadequate [research and development pipeline for – EU DEL] [finance of transdisciplinary and One Health research and development needed for – EU ADD] vaccines, diagnostics, antimicrobials, and alternatives [to antimicrobials – UK ADD / to the use of antimicrobials especially to the use of antibiotics, and to develop innovative tools and methods, including social innovation –. [...] Recognize the benefits of public-private partnerships [such as CARB-X and the Global Antibiotic Research and Development Partnership, – CHE ADD] in the development of [and access to – CHE ADD] antimicrobials, [vaccines, diagnostics and alternatives to antimicrobials – UK ADD] [and in contributing to supply chain sustainability – US ADD], as well as addressing [regulations and – MEX ADD] barriers t. [...] Recognize the important role played by the [public and – EU ADD] private sector in research and development of innovative medicines [and new antimicrobials – EU ADD] and [increase support for the implementation of “delinkage” – EU ADD] [continue to support voluntary initiatives and incentive mechanisms – EU DEL] that separate the cost of investment in research and development from the price and vo.

Authors

CLARK, Jessica

Pages
32
Published in
United States of America

Table of Contents